AMGEN, INC.;THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE S ECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES;BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
发明人:
DEPAOLI, ALEX M.,ORAL, ELIF ARIOGLU,TAYLOR, SIMEON I.,GARG, ABHIMANYU
申请号：
CA2464277
公开号：
CA2464277C
申请日:
2002.10.22
申请国别(地区):
CA
年份:
2013
代理人:
摘要：
Leptin, leptin analogs, and leptin derivatives are used to treat patients withlipodystrophy. Leptin is effective against lipodystrophy conditions for bothgenetic and acquired forms of the disease. A therapeutically effective amountof leptin can be administered in a variety of ways, including in a vectorcomprising nucleic acid sequences encoding leptin. Methods of the presentinvention contemplate administration of leptin, leptin analogs, and leptinderivatives to patients having approximately 4 ng/ml or less before treatment.
